Bitcoin set for a rebound that could stretch toward $100000, BTIG says
Introduction & Market Context
Rigel Pharmaceuticals (NASDAQ:RIGL) presented its third quarter 2025 financial results on November 4, showcasing substantial revenue growth across its product portfolio. Despite reporting a 65% year-over-year increase in net product sales and raising its full-year guidance, Rigel's stock declined 7.83% in aftermarket trading, closing at $30.32, well below its 52-week high of $43.72.
The biopharmaceutical company, focused on developing and commercializing therapies for hematology and oncology, demonstrated continued commercial momentum for its three key products: TAVALISSE, GAVRETO, and REZLIDHIA. This strong performance has allowed Rigel to strengthen its financial position while advancing its pipeline programs.
Quarterly Performance Highlights
Rigel reported Q3 2025 net product sales of $64.1 million, representing a 65% increase compared to Q3 2024. Total revenue for the quarter reached $69.5 million, bolstered by $5.4 million in collaboration revenues from global partners.
The company's flagship product TAVALISSE led the growth with $44.7 million in Q3 sales, a 70% increase year-over-year. GAVRETO and REZLIDHIA also delivered strong performances, with sales of $11.1 million (up 56%) and $8.3 million (up 50%), respectively.
As shown in the following chart detailing Q3 2025 commercial performance:
This robust quarterly performance continues a strong growth trajectory that has been building since 2021. The company's quarterly sales breakdown illustrates consistent growth across all periods:
Financial Position and Outlook
Rigel ended the quarter with $137.1 million in cash, cash equivalents, and short-term investments, a significant improvement from $77.3 million at the end of 2024. This strengthened financial position supports the company's ongoing clinical development programs while maintaining financial discipline.
Based on the strong performance through the first three quarters, Rigel has raised its full-year 2025 guidance. The company now anticipates:
- Total revenue of $285-290 million (previously $270-280 million)
- Net product sales of $225-230 million (previously $210-220 million)
- Contract revenues from collaborations of approximately $60 million
- Positive net income for the full year 2025
The following slide summarizes Rigel's Q3 2025 financial results and updated outlook:
The company's annual net portfolio sales have demonstrated consistent growth, with a 32% CAGR from 2021 to 2025, as illustrated in this projection:
Product Portfolio and Growth Strategy
Rigel's commercial strategy centers on growing its hematology and oncology business through three key products while expanding its development pipeline. The company's approach combines commercial execution with strategic development initiatives:
Beyond the U.S. market, Rigel continues to expand its global footprint through partnerships with Grifols, Kissei, and Medison. These collaborations have enabled commercial availability of TAVALISSE in Japan, key European countries, Canada, Israel, and South Korea, generating $5.1 million in collaboration revenues during Q3 2025.
Pipeline Development and Strategic Collaborations
Rigel is advancing several development programs to expand its product portfolio. The R289 IRAK1/4 inhibitor is being evaluated in a Phase 1b study for relapsed/refractory lower-risk myelodysplastic syndromes (MDS), addressing a significant unmet medical need:
The company has also established strategic collaborations to advance olutasidenib beyond its current indication. These include partnerships with MD Anderson Cancer Center to evaluate olutasidenib in combination with other agents for various myeloid malignancies, and participation in the CONNECT TarGeT Phase 2 clinical study for IDH1-mutated glioma.
Additionally, Rigel announced that multiple abstracts related to its pipeline programs will be presented at the upcoming 67th ASH Annual Meeting:
Market Reaction and Future Catalysts
Despite the strong financial results and raised guidance, Rigel's stock experienced a 7.83% decline in aftermarket trading following the earnings release. This disconnect between financial performance and market reaction may reflect investor concerns about future growth sustainability or competitive pressures in the hematology and oncology space.
Looking ahead, Rigel has outlined several value drivers for the remainder of 2025 and beyond:
During the earnings call, CEO Raul Rodriguez emphasized the company's strategic objectives: "Our strategic objectives are to grow our hematology and oncology business through commercial performance, pipeline expansion, coupled with financial discipline." He also highlighted the company's focus on pursuing in-licensing deals and asset acquisitions that align with its capabilities and strategy.
While the market's immediate reaction was negative, Rigel's strengthened financial position, growing product portfolio, and pipeline advancements provide multiple potential catalysts for future growth. Investors will likely be watching closely for updates on the R289 program and potential new in-licensing opportunities as the company continues to execute its growth strategy in the competitive hematology and oncology market.
Full presentation:
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.